Processing

Please wait...

Settings

Settings

Goto Application

1. WO1996016672 - SERIALLY PASSAGED AFRICAN GREEN MONKEY KIDNEY CELLS

Publication Number WO/1996/016672
Publication Date 06.06.1996
International Application No. PCT/US1995/015118
International Filing Date 30.11.1995
Chapter 2 Demand Filed 07.06.1996
IPC
A61K 39/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
C12N 7/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
CPC
A61K 2039/5252
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
525Virus
5252inactivated (killed)
A61K 2039/5254
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
525Virus
5254avirulent or attenuated
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
C12N 2720/12334
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2720dsRNA Viruses
00011dsRNA Viruses
12011Reoviridae
12311Rotavirus, e.g. rotavirus A
12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N 2720/12351
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2720dsRNA Viruses
00011dsRNA Viruses
12011Reoviridae
12311Rotavirus, e.g. rotavirus A
12351Methods of production or purification of viral material
Applicants
  • DYNCORP [US]/[US]
  • NATIONAL INSTITUTES OF HEALTH [US]/[US]
Inventors
  • CHANOCK, Robert, M.
  • PURCELL, Robert, H.
  • KAPIKIAN, Albert, Z.
  • POTASH, Louis
Agents
  • STEPNO, Norman, H.
Priority Data
08/351,07930.11.1994US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SERIALLY PASSAGED AFRICAN GREEN MONKEY KIDNEY CELLS
(FR) PASSAGE EN SERIE DES CELLULES RENALES DU SINGE VERT AFRICAIN
Abstract
(EN)
The invention described herein provides a method for selecting a novel African Green monkey kidney (AGMK) cell substrate, its cultivation and serial passage and its subsequent characterization. The invention further provides a method for the use of the cell substrate in the isolation, growth and serial passage of a large number of viruses, particularly rotaviruses, enteroviruses, respiratory viruses and hepatitis A virus. A method for the utilization of the AGMK cell substrate for the production of live and killed virus vaccines is also provided.
(FR)
L'invention porte sur un procédé qui permet de sélectionner un nouveau substrat de cellules rénales du singe vert africain (AGMK), sa culture, son passage en série et sa caractérisation ultérieure. L'invention concerne aussi un procédé permettant d'utiliser le substrat de cellules pour l'isolement, la croissance et le passage en série d'un grand nombre de virus, notamment les rotavirus, les entérovirus, les virus des voies respiratoires et les virus de l'hépatite A. L'invention comprend également un procédé permettant d'utiliser le substrat de cellules AGMK pour produire des vaccins à virus actif et des vaccins à virus inactivé.
Latest bibliographic data on file with the International Bureau